Bacterial Pneumonia - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 50 pages report, published by Global Markets Direct

Keywords : Bacterial Pneumonia Therapeutic Products under Development, Key Players in Bacterial Pneumonia Therapeutics, Bacterial Pneumonia Pipeline Overview, Bacterial Pneumonia Pipeline, Bacterial Pneumonia Pipeline Assessment

Report ThumbnailSeptember-2013
Bacterial Pneumonia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bacterial Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia. Bacterial Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Pneumonia.
- A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial Pneumonia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Bacterial Pneumonia, H2 2013 7
  • Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Route of Administration, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Molecule Type, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 22
  • List of Tables
  • Number of Products Under Development for Bacterial Pneumonia, H2 2013 7
  • Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Rib-X Pharmaceuticals, Inc., H2 2013 14
  • Paratek Pharmaceuticals, Inc., H2 2013 15
  • Bayer AG, H2 2013 16
  • Trius Therapeutics, Inc., H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 22
  • Bacterial Pneumonia Therapeutics - Drug Profile Updates 35
  • Bacterial Pneumonia Therapeutics - Dormant Products 42
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Bacterial Pneumonia Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Bacterial Pneumonia 7
  • Bacterial Pneumonia Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Bacterial Pneumonia Therapeutics - Products under Development by Companies 13
  • Companies Involved in Bacterial Pneumonia Therapeutics Development 14
  • Rib-X Pharmaceuticals, Inc. 14
  • Paratek Pharmaceuticals, Inc. 15
  • Bayer AG 16
  • Trius Therapeutics, Inc. 17
  • Bacterial Pneumonia - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Drug Profiles 23
  • amikacin - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • omadacycline tosylate - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • Gyrase Program - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • tedizolid phosphate - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • RX-P770 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • IMV-0123 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • MAb Against S aureus - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Bacterial Pneumonia Therapeutics - Drug Profile Updates 35
  • Bacterial Pneumonia Therapeutics - Dormant Products 42
  • Bacterial Pneumonia - Product Development Milestones 43
  • Featured News & Press Releases 43
  • Apr 16, 2013: Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution In Mechanically Ventilated Patients With Gram-negative Pneumonia 43
  • Oct 16, 2012: Cubist Pharma To Feature Clinical Data On CXA-201 At Inaugural IDWeek Annual Meeting 43
  • Oct 08, 2012: Cempra Announces Phase I Study Results Of Intravenous Solithromycin 44
  • Sep 05, 2012: Rib-X Pharma To Present Data On Antibiotic Candidate Radezolid At ICAAC 2012 44
  • Apr 13, 2012: Cempra To Present Overview On Solithromycin At Future Leaders In Biotechnology Industry Conference 45
  • Apr 02, 2012: Tetraphase Presents Data On TP-834 At 22nd European Congress Of Clinical Microbiology And Infectious Disease 45
  • Apr 02, 2012: Dong Wha Pharma Announces Initiation Of Phase III Trial Of Its Antibacterial Agent DW224a 46
  • Mar 31, 2012: Cempra Presents Phase II Clinical Trial Data Of CEM-101 In Community-Acquired Bacterial Pneumonia Patients At ECCMID 46
  • Mar 29, 2012: Cempra To Present Clinical Data Of CEM-101 At Needham Health Care Conference 47
  • Mar 28, 2012: Paratek Wins Agreement With FDA On Special Protocol Assessment For Phase III Study In Community-Acquired Bacterial Pneumonia 47
  • Appendix 49
  • Methodology 49
  • Coverage 49
  • Secondary Research 49
  • Primary Research 49
  • Expert Panel Validation 49
  • Contact Us 50
  • Disclaimer 50

Please select a license type

Share

Related Products

Global Markets DirectBacterial Pneumonia - Pipeline Review, H2 2013Product ThumbnailBacterial Pneumonia - Pipeline Review, H2 2013, Industry ReportProduct #: 113322
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved